Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
August 7, 2017 4:01 PM EDTWebcast and Conference Call today at 4:30 p.m. ET
Cash and marketable securities totaled $235.3 million at June 30, 2017 Royalty revenue for the quarter was $7.5 million Milestone payments totaling $65 million earned following AbbVies EU approval of MAVIRET (glecaprevir/pibrentasvir) in July, and U.S. approval of MAVYRET (glecaprevir/pibrentasvir) in August RSV and NASH/PBC clinical programs continue to advance toward new stages next quarterWATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta... More
